The emergence of novel respiratory infections (eg, COVID-19) and expeditious development
of nanoparticle-based COVID-19 vaccines have recently reignited considerable interest in …

Drug administration by inhalation is a well-established approach to treat respiratory and
systemic diseases. To deliver a drug into the lung dry powder inhalation (DPI) is an …

With the development of nanotechnology and confronting the problems of traditional
pharmaceutical formulations in treating lung diseases, inhalable nano-formulations have …

The lack of effective treatments for pulmonary diseases presents a significant global health
burden, primarily due to the challenges posed by the pulmonary barrier that hinders drug …

Pulmonary administration of inhalable nanoparticles (NPs) is an emerging area of interest.
Dry powder inhalers may offer particular advantages for pulmonary administration of NPs …

Background Dry powder inhalation (DPI) formulations have been widely studied for the
treatment of respiratory diseases, including COVID-19, which have become common and …

We are providing an update to our previously published review paper on inhaled
nanoparticles, thus updating with the most recent reports in the literature. The field of …

Introduction: The number of pulmonary diseases that are effectively treated by aerosolized
medicine continues to grow. Areas covered: These diseases include chronic obstructive …

Chronic pulmonary diseases encompass different persistent and lethal diseases, including
chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic …

Nanoparticles are extensively studied for drug delivery and are proving to be effective in
drug delivery and the diagnostic field. Drug delivery to lungs has its advantages over other …